<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1171">
  <stage>Registered</stage>
  <submitdate>17/03/2006</submitdate>
  <approvaldate>20/03/2006</approvaldate>
  <actrnumber>ACTRN12606000104550</actrnumber>
  <trial_identification>
    <studytitle>Chronic dietary modification versus supplementation with glycine betaine, on fasting and post-methionine load homocysteine concentrations in healthy volunteers.</studytitle>
    <scientifictitle>A study to compare dietary modification versus supplementation with glycine betaine, on fasting and post-methionine load homocysteine concentrations in healthy volunteers.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Healthy volunteers</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2 />
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Subjects will receive 2 treatments (a or b) in random order.  Treatment a is a diet rich in glycine betaine (approximately 1500mg per day).                                                                         The treatment duration will be two weeks, followed by a one week wash out period, and then a further two weeks on the alternative treatment.</interventions>
    <comparator>Treatment b is a glycine betaine supplementation regime (3x 500mg tablets each day).</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Homocysteine concentrations</outcome>
      <timepoint>At 1, 3, 7, 10, 14, 16 and 20 days post-treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma glycine betaine, choline, methionine, and urine glycine betaine and choline concentrations.</outcome>
      <timepoint>At  1, 3, 7, 10, 14, 16 and 20 days post-treatment. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>For each treatment period, duplicate food samples will be also be assayed for glycine betaine and choline measurement to confirm the amount ingested.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy volunteers with no previous history of vascular disease and no illness requiring medication, normal homocysteine concentration.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria> The presence of vitamin B12, vitamin B6 or folate deficiency, and/or 677-&gt;T polymorphisms in the methylene reductase gene.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed envelopes</concealment>
    <sequence>Sequence generated using simple randomisation generated by computer software.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Bio-availability</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/05/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>8</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Canterbury Health Laboratories</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>National Heart Foundation</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>People with high blood levels of homocysteine are more likely to have heart attacks. Betaine helps keep homocysteine levels down. Many foods (including wheat-based breakfast cereals and some vegetables) are rich in betaine. In addition, betaine (also called trimethylglycine) can be purchased as a dietary supplement from health food stores. This research will investigate which approach has the greatest influence on homocysteine levels over a prolonged time period, eating more betaine in the diet or taking betaine in the form of dietary supplements.  We hope to learn more about how betaine can be most effectively used to lower homocysteine and  decrease the risk of heart attacks.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Canterbury Health Laboratories</ethicname>
      <ethicaddress />
      <ethicapprovaldate>21/02/2006</ethicapprovaldate>
      <hrec>URA/06/02/002</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Wendy Atkinson</name>
      <address>Clinical Biochemistry Department
Canterbury Health Laboratories
PO Box 151
Christchurch</address>
      <phone>+64 3 3641594</phone>
      <fax />
      <email>wendy.atkinson@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Wendy Atkinson</name>
      <address>Clinical Biochemistry Department
Canterbury Health Laboratories
PO Box 151
Christchurch</address>
      <phone>+64 3 3641594</phone>
      <fax />
      <email>wendy.atkinson@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>